CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial

Digital transformation conceptual for next generation technology era

A CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, Dana-Farber Cancer Institute investigators report at the 64th American Society of Hematology (ASH) Annual Meeting.

Elon Musk is finally relaunching Twitter Blue

Previous article

Jimmy Fallon, Paris Hilton, and a slew of celebrities sued over promoting Bored Ape Yacht Club NFTs

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations